Intravenous Immunoglobulin in Treating Nonventilated COVID-19 Patients With Moderate-to-Severe Hypoxia: A Pharmacoeconomic Analysis

ntravenous immunoglobulin (IVIG) has been available in most hospitals for 4 decades, with broad therapeutic applications in the treatment of Kawasaki disease and a variety of inflammatory, infectious, autoimmune, and viral diseases, via multifactorial mechanisms of immune modulation. 1 Reports of COVID-19-associated multisystem inflammatory syndrome in adults and children have supported the use of IVIG in treatment. Previous studies of IVIG treatment for COVID-19 have produced mixed results. Although retrospective studies have largely been positive, 4-8 prospective clinical trials have been mixed, with some favorable results However, there is still considerable debate regarding whether some subgroups of patients with COVID-19 may benefit from IVIG; the studies that support this argument, however, have been diluted